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Abstract 
Purpose: Cellular immune dysfunctions, which are common in intensive care patients, predict a number of signifi‑
cant complications. In order to effectively target treatments, clinically applicable measures need to be developed to 
detect dysfunction. The objective was to confirm the ability of cellular markers associated with immune dysfunction 
to stratify risk of secondary infection in critically ill patients.
Methods: Multi‑centre, prospective observational cohort study of critically ill patients in four UK intensive care units. 
Serial blood samples were taken, and three cell surface markers associated with immune cell dysfunction [neutrophil 
CD88, monocyte human leucocyte antigen‑DR (HLA‑DR) and percentage of regulatory T cells  (Tregs)] were assayed 
on‑site using standardized flow cytometric measures. Patients were followed up for the development of secondary 
infections.
Results: A total of 148 patients were recruited, with data available from 138. Reduced neutrophil CD88, reduced 
monocyte HLA‑DR and elevated proportions of  Tregs were all associated with subsequent development of infection 
with odds ratios (95% CI) of 2.18 (1.00–4.74), 3.44 (1.58–7.47) and 2.41 (1.14–5.11), respectively. Burden of immune 
dysfunction predicted a progressive increase in risk of infection, from 14% for patients with no dysfunction to 59% for 
patients with dysfunction of all three markers. The tests failed to risk stratify patients shortly after ICU admission but 
were effective between days 3 and 9.
Conclusions: This study confirms our previous findings that three cell surface markers can predict risk of subsequent 
secondary infection, demonstrates the feasibility of standardized multisite flow cytometry and presents a tool which 
can be used to target future immunomodulatory therapies.
Trial registration: The study was registered with clinicaltrials.gov (NCT02186522).
Keywords: Cross infection, Immunoparesis, Immunophenotyping, Monocytes, Neutrophils, T‑lymphocytes, 
regulatory
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Introduction
Critical illness occurs when a sterile [1, 2] or infective [3] 
insult leads to organ dysfunction [4]. A hallmark of criti-
cal illness is systemic inflammation and immune-medi-
ated organ damage [5]. However it is increasingly clear 
that this immune activation is accompanied by an equally 
pronounced immunodepression [6], and that a persis-
tence of this immune duality is associated with a com-
plicated intensive care unit (ICU) course [7]. If effective 
treatments for this complex state of immune dysfunction 
are to be developed, we need to identify clinical and labo-
ratory markers for it.
A significant complication in intensive care is the 
development of nosocomial infection, which occurs in 
20–40% of patients [8]. The development of such infec-
tions is relevant to patients and the healthcare system, as 
they are associated with increased morbidity, mortality, 
prolonged need for organ support, and greater overall ill-
ness costs [8]. ICU-acquired infections are also a major 
driver of antibiotic use, which contributes to increased 
antimicrobial resistance and the risk of drug toxicity [9]. 
We, and others, have previously demonstrated a strong 
association between immune dysfunction and the subse-
quent development of nosocomial infection [1, 3].
We previously published the findings of a single-
centre study examining three markers associated with 
immune dysfunction [3], namely neutrophil CD88 (as 
a marker of C5a-mediated neutrophil dysfunction [10, 
11]), monocyte human leucocyte antigen-DR (HLA-DR) 
(as a marker of monocyte deactivation [12, 13]) and the 
proportion of regulatory T cells  (Tregs, associated with an 
increased risk of secondary infection [14]). These three 
markers independently, and additively, predicted the sub-
sequent development of nosocomial infection [3].
The results of single-centre studies can be hard to rep-
licate, but development of clinically useable measures of 
immune function to guide trials of immunomodulatory 
therapy in critical illness [15] requires accurate, reproducible 
immunophenotyping tools. The aim of the ImmuNe Fail-
urE in Critical Therapy study was to confirm our previously 
identified markers associated with immune dysfunction, 
and their ability to identify risk of subsequent nosocomial 
infection in a multicentre study, using standardized flow 
cytometry. Some of the results of these studies have been 
previously reported in the form of an abstract [16].
Methods
The study protocol has been published [17]. The study 
was approved by National Health Service Research Eth-
ics Committees and was performed in accordance with 
the ethical standards laid down in the 1964 Declaration 
of Helsinki and its later amendments.
Setting and participants
Patients were recruited from the four participating ICUs, 
based in the UK. Details of the recruiting units are shown 
in the supplemental section (Table S1). Inclusion criteria 
were adult patients admitted to ICU and receiving either 
invasive mechanical ventilation or two or more other 
organ systems support, who were predicted to remain in 
ICU for at least 48 h [17]. Written, informed assent was 
obtained from the nearest relative or personal consultee, 
and retrospective consent was sought from all patients 
who regained capacity. A full list of exclusion criteria is in 
the supplemental section.
Sampling schedule
Tripotassium ethylenediaminetetraacetate (K3-EDTA) 
anticoagulated blood samples were taken on the day of 
study enrolment, and then at 2-day intervals until day 12 
with patients being followed for determination of infec-
tion to day 16. Patients discharged to hospital wards 
remained in the study. Patients discharged home during 
the study period were followed up using hospital records 
to ascertain re-admission with infection.
Definition of infection
We used methods developed in our previous study to 
identify infection [3, 17]. Briefly, researchers blinded to 
the immune phenotyping data assessed patients for the 
development of infections which were defined using the 
Hospitals in Europe Link for Infection Control through 
Surveillance criteria [18] (see supplemental methods). 
Suspected infections that did not meet the criteria for con-
firmed infection underwent independent, blinded review 
by two expert intensive care clinicians (see supplemental 
methods). The onset of infection was defined as the time 
the relevant microbiology sample was taken. Only the first 
infection was defined as the outcome of interest.
Flow cytometric standardization and sample staining
All sites used the same flow cytometry analyser, the 
FACS Canto II (BD Biosciences, San Jose, CA, USA), and 
antibodies from the same batch, using study standard 
operating procedures. Machines were standardized by 
monthly matching of target values using a common batch 
Take home message 
ΓÇÿSecondary infections are a major concern in intensive care 
and have been convincingly associated with immune dysfunction 
occurring as a result of critical illnesses. Effective targeting of immu‑
nomodulatory therapies requires the ability to identify patients who 
are at risk, and this study presents three immune cell markers which 
additively predict the risk of subsequent secondary infectionΓÇÖ
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of Cytometry Setup and Tracking (CS&T) beads (BDB), 
and daily internal quality control using the same com-
mon batch of CS&T beads. Details of the fluorophores 
and antibodies are reported in Table S2.
Immunophenotyping measures
The primary measures were those used in the published 
study [3], namely surface neutrophil CD88 (nCD88, as 
a marker associated with C5a-mediated neutrophil dys-
function [10, 11]), monocyte HLA-DR (mHLA-DR, as a 
marker associated with monocyte deactivation [19]) and 
the proportion of CD4 T  cells expressing a regulatory 
phenotype  (CD4+/CD25++/CD127− Tregs) [3, 20]. These 
were compared against simple enumeration of leucocyte 
populations and lymphocyte to neutrophil ratios which 
have previously been reported to be predictive of subse-
quent infection [21, 22].
A study of the reliability and reproducibility of the meas-
ures of cell surface markers was conducted as set out in the 
published protocol [17] (see supplemental section).
Defining cut‑off for ‘dysfunction’
Changes in antibody clones, fluorophores and flow 
cytometers necessitated by the multicentre standardiza-
tion process meant we were unable to directly compare 
the marker values from the current study and the previ-
ous study [3]. Therefore, we re-derived optimum cut-off 
values for cell-surface markers using receiver operating 
characteristic (ROC) curve analysis, defining ‘dysfunc-
tion’ and ‘no dysfunction’ using the same method [3]. 
Briefly, patients were categorized using values from the 
sample taken most proximally to the relevant clinical 
end-point (death, infection or discharge without infec-
tion). For patients who acquired an infection, the sample 
used was the one taken closest to but preceding the 48-h 
time point before the infection. This was chosen to iden-
tify markers that changed prior to infection developing.
Statistical analysis
Statistical analysis followed the statistical analysis plan 
that was finalized prior to database lock (see supplemen-
tal section). The sample size calculation is set out in the 
protocol paper [17]. Assuming a 35% nosocomial infec-
tion rate [3], to estimate a 50% positive predictive value 
with 95% confidence interval width of 39–61% would 
require 200 patients. Optimum cut-offs were defined by 
constructing ROC curves comparing values from sam-
ples 48 h before an infection with samples from patients 
who did not develop infection, using Youden’s index [23]. 
Post hoc analyses to adjust for clinical and demographic 
predictors of infection were undertaken; these were not 
prespecified in the analysis plan but were included in 
response to independent review.
Modelling potential clinical use
In a pre-planned evaluation of the clinical potential for 
these markers to alter decision-making [17], we exam-
ined the ability of the immune dysfunction measure-
ments to predict subsequent infection, ICU length of stay 
and duration of organ support. We used the optimum 
cut-offs from ROC analysis and calculated their predic-
tive ability when measured at baseline, and days 2–4, 6–8 
and 10–12 post study enrolment. We chose these time 
points as clinically relevant times at which the immune 
phenotyping might be undertaken and operationalised in 
routine care. We modelled predictive performance with 
a two-step process: first, using the best-performing test 
(monocyte HLA-DR) to select patients with low HLA-
DR; and second, then classifying patients with either low 
neutrophil CD88 or elevated  Tregs (or both) as ‘highest 
risk’.
Results
Recruitment and development of infection
We recruited 148 patients. Time and budgetary restraints 
limited recruitment of the predefined numbers. Supple-
mental Fig.  S1 shows the recruitment diagram.  A total 
of 138 patients were available for analysis. Patients were 
enrolled a median 1.5 days (IQR 0.7–2 days) after admis-
sion to ICU. Demographic and clinical data are shown in 
Table 1.
In total 51 (37%) patients developed secondary infec-
tions after study entry; 34 (67%) met the criteria for con-
firmed infection whilst 17 (33%) were deemed “highly 
likely” on expert review. Infection sites, organisms and 
relationship to primary infection are summarised in sup-
plemental Table S3. Infection occurred a median 7 days 
(IQR 3–11) after ICU admission. In nine patients, infec-
tion developed within 48 h of study entry; these patients 
were excluded from the ROC analysis, but included in a 
sensitivity analysis.
Association of markers of immune dysfunction 
with subsequent infection
The three tests all demonstrated high intra- and inter-
rater reliability (see supplemental results section).
Reduced nCD88, reduced mHLA-DR and elevated 
proportions of  Tregs were all associated with subsequent 
development of infection when applying optimal ROC 
cut-offs (Table 2); odds ratios (95% CI) were 2.18 (1.00–
4.74), 3.44 (1.58–7.47) and 2.41 (1.14–5.11), respectively. 
Area under the ROC curve for each marker is reported 
in the supplemental section (Table S4). None of the clini-
cal or demographic variables were significant independ-
ent predictors of subsequent infection. Adjustment for 
potential confounding by these variables did not result 
in significant changes to the unadjusted odds ratios 
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(Table S5). Values plotted for each marker dichotomised 
by group (did versus did not develop infection) on the dif-
ferent days before infection events occurred showed that 
changes in CD88 and HLA-DR tended to occur 2–3 days 
prior to the events (supplemental results Fig. S2a, b).
Marker performance in survival analysis
In survival analysis, all three measures showed a sig-
nificant association with the hazard of infection 
(Fig.  1a–c). As for the odds ratios, adjustment for 
Table 1 Clinical and demographic features of patients who did and did not develop secondary infection following admis-
sion to intensive care
IQR interquartile range, SD standard deviation, APACHE acute physiology and chronic health evaluation, SOFA sequential organ failure assessment, CVC central venous 
catheter
Parameter Infection (51) No infection (87)
Age (years), median (IQR) 66 (48–74) 65 (53–74)
Male gender, n (%) 32 (63%) 55 (63%)
Mean (SD) functional co‑morbidity index score 2.0 (2.2) 1.8 (1.6)
Smoking status
 Current 15 (29%) 21 (24%)
 Ex‑smoker 11 (22%) 19 (22%)
 Non‑smoker 18 (35%) 27 (31%)
 Unknown 7 (14%) 20 (23%)
Admission reason (some patients fall into both ‘sepsis’ and one other category)
 Sepsis 15 (29%) 40 (46%)
 Surgery 16 (31%) 16 (18%)
 Trauma 5 (10%) 2 (2%)
 Other 19 (37%) 39 (45%)
APACHE II score, mean (SD) 14.6 (6.7) 15.4 (6.3)
SOFA score, mean (SD) 4.8 (2.5) 5.5 (3.1)
Admission white cell count/mm3, median (IQR) 12,900 (9100–16,800) 11,950 (7900–14,250)
Admission neutrophil count/mm3, median (IQR) 10,360 (7000–14,140) 9200 (7000–12,200)
Admission lymphocyte count/mm3, median (IQR) 1140 (750–1780) 1000 (620–1500)
Arterial line 51 (100%) 87 (100%)
CVC 48 (94%) 78 (89%)
Endotracheal tube 51 (100%) 86 (99%)
Enteral/parenteral nutrition 47 (93%)/9 (18%) 82 (94%)/8 (9%)
Urinary catheter 51 (100%) 85 (98%)
Corticosteroids (< 400 mg hydrocortisone‑equivalent/24 h) 18 (35%) 37 (43%)
Stress ulcer prophylaxis 49 (96%) 80 (92%)
Antibiotics in 72 h prior and/or within 24 h of ICU admission 41 (80%) 79 (91%)
ICU length of stay in days, median (IQR) 15 (10–24) 7 (5–14)
Mortality
 ICU 7 (14%) 20 (23%)
 Hospital 18 (35%) 26 (30%)
 Infection related 12 (67%) 10 (39%)
Table 2 Predictive performance of markers at the optimal cut-offs defined by ROC analysis
Numbers are point estimate (95% CI). CD88 and monocyte HLA-DR are expressed in arbitrary fluorescence units
Spec specificity, Sens sensitivity, NPV negative predictive value, PPV positive predictive value, OR odds ratio
Marker Cut‑off Spec Sens NPV PPV OR
CD88 ≤ 9609 0.49 (0.39–0.60) 0.69 (0.53–0.82) 0.77 (0.64–0.87) 0.39 (0.29–0.52) 2.18 (1.00–4.74)
Monocyte HLA‑DR ≤ 2009 0.63 (0.52–0.73 0.67 (0.51–0.8) 0.80 (0.68–0.88) 0.47 (0.34–0.60) 3.44 (1.58–7.47)
Tregs as  % of CD4 cells ≥ 12.12 0.64 (0.53–0.74) 0.57(0.41–0.72) 0.76 (0.64–0.85) 0.44 (0.30–0.58) 2.41 (1.14–5.11)
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clinical/demographic variables did not result in signifi-
cant changes to the hazard ratios (see Table S5).
Baseline marker values did not predict subsequent 
infection, with or without adjustment for clinical vari-
ables (supplemental Table S6).
Additional and sensitivity analyses
Sensitivity analyses that included patients who devel-
oped secondary infection within the 48-h window of first 
blood sampling are shown in the supplement (Table S7). 
The relationships between the markers and other clini-
cal outcomes, namely length of stay, days alive and free of 
organ support, and SOFA scores are shown in the supple-
ment (Tables S8, S9).
We found no predictive value for total leucocyte or dif-
ferential counts (supplemental Table S10).
Marker combinations for predicting subsequent infection
Using the best cut-offs derived from the ROC analy-
sis for each of the three biomarkers, we assigned each 
‘dysfunction’ a score of 1 (no dysfunction scored 0). The 
number of dysfunctions was summed to give a cumula-
tive total (range 0–3). With this approach, an increase in 
the number of immune dysfunctions was associated with 
a progressive increase in the risk of subsequent infec-
tion (Table 3, Fig. 1d). When the combined markers were 
used, the area under ROC curve (AUC ROC) was 0.72 
(95% CI 0.62–0.81); this was larger than each individual 
biomarker AUC (range 0.57–0.64; Table S4). Adjustment 
for potential clinical confounders did not significantly 
alter this relationship (Table S11).
Modelling of clinical use
The modelling of potential clinical use of these tests, 
which would most likely be to guide immunomodulatory 
therapy, aimed to dichotomise patients into particularly 
‘low’ risk (unlikely to benefit from immunomodulation) 
and ‘high’ risk (immunomodulation potentially could 
modify risk) for subsequent infection.
When the clinical modelling strategy set out in the 
“Methods” was used, the sample taken at study baseline 
demonstrated no significant ability to predict subsequent 
infection (see Table  4, Figure S3a), similar to the analy-
sis of single markers at baseline (Table S6). In sensitivity 
analyses that selected higher sensitivity thresholds for 
‘low’ monocyte HLA-DR, there was no improvement 
in the predictive ability of the test at baseline (data not 
shown).
In contrast, the sample taken between study days 2 and 
4 had potentially useful discriminant value for patients 
at low and high risk of subsequent secondary infection 
(see Table 4, Fig. S3b). ‘High-risk’ patients also had lower 
infection-free survival on survival analysis [HR 2.8 (95% 
CI 1.4–5.7) p = 0.005 by log-rank test], and significantly 
longer ICU length of stay and duration of organ support 
Fig. 1 Survival curves for patients dichotomised by markers at the 
cut‑offs shown. a Neutrophil CD88 expression, b total monocyte 
HLA‑DR expression, c  Tregs as a  percentage of all  CD4
+ cells. d Addi‑
tive combination of markers p value by log‑rank test (panels a–c) and 
log‑rank test for trend (panel d). Hazard ratios for combined markers 
are shown in Table 3
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(Table  4). This predictive ability was also found at days 
6–8. A similar, but non-statistically significant, pattern 
was also found at days 10–12 (Table 4). Adjustment for 
potential clinical confounders did not significantly alter 
the predictive ability of these markers at any of the time 
points examined (Table  S12). Selecting higher sensitiv-
ity thresholds for ‘low’ monocyte HLA-DR increased 
the overall sensitivity of the test but this occurred at the 
expense of specificity (data not shown).
In a hypothetical model of enriching a trial popula-
tion with ‘high-risk’ patients for an immunomodulatory 
intervention, we found the numbers of patients needed to 
treat (and consequently the size of any trial) could likely 
be substantially reduced using this precision-medicine 
approach (see Tables  S13, S14, supplemental section). 
For example, if this strategy was used to enrol high-risk 
patients based on a test carried out on ICU day 3–5 post 
admission, a 30% relative risk reduction in subsequent 
infection (80% power) could be detected with a sample 
size of 436, compared to 806 if ‘all comers’ were included.
Discussion
This is the first report of multicentre, multiparametric 
immunophenotyping for the determination of immune 
dysfunction amongst critically ill adults and one of 
only two studies [3] to examine multiple markers over 
time. Through this study we have confirmed the role of 
three markers associated with leucocyte dysfunction 
in predicting the development of nosocomial infection. 
Although each marker alone had relatively modest pre-
dictive ability, in combination they had stronger associa-
tion with the risk of infection. These results are strikingly 
similar to our previous findings providing confirmatory 
evidence [3].
The demographic and clinical data (Table  1) demon-
strate that the patients were broadly similar at the time of 
study enrolment regardless of whether they subsequently 
develop an infection, and had similar severity of illness 
scores and requirement for organ support on ICU admis-
sion. Adjustment for these factors did not alter the pre-
dictive ability of the cell-surface markers (see Tables S5, 
S11–12). These findings contrast with other studies 
which found that age and illness severity are strong 
predictors of subsequent nosocomial infection [24]. This 
discrepancy may be explained by differences between the 
cohorts of patients recruited. We deliberately recruited 
a group of patients who were already at high risk of 
secondary infection, confirmed by the 37% incidence 
observed. The markers we present have also been associ-
ated with severity of illness [25–27], and therefore their 
use will already encode similar information to that con-
tained in severity scores. We contend that in the severely 
ill patient cohort we studied, clinical and demographic 
features are unlikely to reliably discriminate risk of sub-
sequent infection.
We found that measuring immune dysfunction with 
the baseline sample (taken a median 1.5  days after ICU 
admission) shows poor predictive ability for subsequent 
infections. By contrast, samples taken between study days 
2 and 8 (median 3–9 days after ICU admission) had bet-
ter predictive ability for subsequent infections, and were 
also associated with longer ICU stay and greater need for 
organ support. The median time to infection from a posi-
tive test on the day 2–4 sample was 5 days, which appears 
a plausible interval in which an immunostimulatory ther-
apy could work [28]. Using this approach would allow 
targeting of immunomodulatory therapies to patients 
who might have greatest risk–benefit balance from these 
therapies especially through reduction in secondary 
infections. This might also translate into reduced length 
of stay and infection-associated morbidity and mortality 
[28]. The impact of nosocomial infection on mortality is 
relatively limited [24], but the costs of prolonged hospital 
stay and organ support are significant and could be sig-
nificantly  substantially impacted on by targeted immu-
notherapy. A precision medicine approach has greatest 
chance of cost-effectiveness given the potential high cost 
of these therapies.
It is interesting to note that patients who developed 
secondary infections demonstrated an impaired recovery 
in both monocyte HLA-DR and neutrophil CD88 relative 
to those who did not develop infections (Fig. S2), suggest-
ing that persistence of dysfunction is an important risk 
factor for subsequent infection, similar to an association 
reported in trauma patients [1]. Whether immunomodu-
latory therapies should be started at ICU admission and 
Table 3 Predictive performance of additive combination of the three markers
Analysis of odds ratio (OR) by logistic regression and hazard ratios (HR) from Cox proportional hazards model. Adjusted analysis reports results adjusted for SOFA 
score, comorbidity and use of steroids
Number of dysfunctions n Infections 95% CI for proportion OR (95% CI) Adjusted OR HR Adjusted HR
0 21 3 (14%) (5–35%) Indicator Indicator Indicator Indicator
1 45 7 (16%) (8–29%) 1.1 (0.25–4.7) 1.00 (0.22–4.41) 1.53 (0.41–5.64) 1.20 (0.30–4.49)
2 46 22 (48%) (34–62%) 5.5 (1.4–21.3) 5.10 (1.30–19.99) 6.04 (1.83–20.00) 5.19 (1.55–17.42)
3 17 10 (59%) (36–78%) 8.5 (1.8–40.7) 8.31 (1.70–40.71) 6.00 (1.65–21.90) 6.62 (1.81–24.21)
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modified at days 3–5, or not started until days 3–5 will 
need to be determined by future randomized controlled 
trials.
Our study has a number of strengths. By using com-
mon protocols and reagents, the same model of flow 
cytometry analyser and cross-site standardization, we 
have been able to obtain comparable results from geo-
graphically and clinically diverse units. We have also been 
able to explore a number of putative markers of immune 
dysfunction, validating two, which we had established 
previously alongside the benchmark monocyte HLA-DR.
We used rigorous criteria for the determination of 
infection, and expert consensus for those suspected 
infections that did not meet the criteria. Sensitivity 
analyses demonstrated considerable overlap in the 95% 
confidence intervals for the predictive performance of 
the markers, either when early (< 48  h after enrolment, 
Table  S7) or only confirmed infections were included 
(data not shown).
The fields of immunophenotyping and critical illness-
induced immune dysfunction are relatively new, and as 
such there are no established benchmarks or levels for 
defining ‘normal’ and ‘abnormal’ measures. Although this 
study used development of infection to define cut-offs 
for immune dysfunction, further external validation of 
markers at these specific cut-offs is required. At present 
the assays need a high degree of machine standardiza-
tion and further work is required to extend their usabil-
ity to different flow cytometers or towards a near-patient 
test. The extension of the existing QuantiBRITE system 
(BD Biosciences, San Jose, CA) used for monocyte HLA-
DR quantification to other fluorophores and other cell 
surface markers would be one potential solution to this 
issue.
Whilst the tests presented have relatively modest per-
formance against typical ‘diagnostic’ tests, they are not 
designed to diagnose secondary infection, but rather to 
stratify the risk of developing secondary infection. As 
such the markers show comparable performance to risk 
markers used in other acute illnesses, such as predictors 
of mortality in acute exacerbations of chronic obstructive 
pulmonary disease [29] or major cardiac events in unsta-
ble angina [30]. Monocyte HLA-DR is in current use for 
risk stratification in clinical trials (NCT02361528), and 
we demonstrate in this study that its predictive ability is 
significantly enhanced by the addition of the two addi-
tional markers. As we demonstrate in modelling poten-
tial use (Tables S13, 14), the use of these markers could 
substantially alter the conduct of trials of immunomodu-
latory therapies, thus increasing the likelihood of success-
ful trials and potentially increasing the cost-effectiveness 
of such novel therapies.
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In conclusion, our study confirms our previous findings 
of the ability of neutrophil CD88, monocyte HLA-DR 
and the percentage of  Tregs to predict secondary infection 
in patients requiring intensive care and organ support, 
and provides novel data on the time course of dysfunc-
tion and clinical relevance of the optimum timing of sam-
pling in predicting risk of infection. The combination of 
markers allows for a more nuanced assessment of infec-
tion risk, with important implications for developing 
stratified medicine tools to support future immunomod-
ulatory therapies amongst this group of patients.
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